

## Certificate of Analysis

### TSSK2, active

(Recombinant enzyme expressed in Sf21 insect cells)

Item # 14-632, 14-632-K, 14-632M

Parent Lot # D8KN010U

The data presented in this document apply to the parent lot shown above and to all pack sizes derived from subsequent vialing runs of this parent lot. An alphabetical suffix after the parent lot number is used to denote each vialing run.

**Product Description:** N-terminal 6His-tagged, recombinant, full length, human TSSK2, expressed by baculovirus in Sf21 insect cells. Purified using Ni<sup>2+</sup>/NTA agarose. Purity 74% by SDS-PAGE and Coomassie blue staining. MW = 44.8kDa.

**Specific Activity (Parent lot# D8KN010U):** 1552U/mg, where one unit of TSSK2 activity is defined as 1nmol phosphate incorporated into 100µM CHKtide per minute at 30°C with a final ATP concentration of 100µM.

**Formulation:** 2.718mg/ml of enzyme in 50mM Tris/HCl pH7.5, 300mM NaCl, 0.1mM EGTA, 0.03% Brij-35, 270mM sucrose, 1mM benzamidine, 0.2mM PMSF, 0.1% 2-mercaptoethanol. Frozen solution.


**Storage and Stability:** On receipt of material store at -70°C. Unopened reagent is stable for a minimum of 6 months from date of shipment when stored at recommended storage temperature. Avoid repeat freeze/thaw cycles. For maximum recovery of product, centrifuge original vial prior to removing the cap.

**Handling Recommendations:** Rapidly thaw the vial under cold water and immediately place on ice. Aliquot unused material into pre-chilled microcentrifuge tubes and immediately snap-freeze the vials in liquid nitrogen prior to re-storage at -70°C.


**FOR IN VITRO RESEARCH USE ONLY  
NOT FOR USE IN HUMANS OR ANIMALS**

### Quality Control Testing

**Kinase Assay:** 1.8–13.6ng of this lot of enzyme phosphorylated 0.1mM CHKtide in the assay described on page two. Assay background was subtracted from the actual counts to yield the results shown below.



**MS Tryptic Fingerprint:** Confirmed identity as TSSK2 with the translated native sequence listed on page three.



## Certificate of Analysis

### Kinase Assay Protocol

#### Stock Solutions:

- 1. 5 x Reaction Buffer:** 40mM MOPS/NaOH pH7.0, 1mM EDTA.
- 2. CHKtide:** Use at a final assay concentration of 100 $\mu$ M. Prepare a 1mM stock and add 2.5 $\mu$ l of stock per assay point.
- 3. TSSK2, active:** Dilute with 20mM MOPS/NaOH pH7.0, 1mM EDTA, 0.01% Brij-35, 5% glycerol, 0.1% 2-mercaptoethanol, 1mg/ml BSA. Use 1.8–13.6ng per assay point.
- 4. [ $\gamma$ -<sup>33</sup>P]ATP:** 2.5 x magnesium acetate/[ $\gamma$ -<sup>33</sup>P]ATP cocktail: 25mM MgAc and 0.25mM ATP to which is added [ $\gamma$ -<sup>33</sup>P]ATP (specific activity approximately 500 - 800cpm/pmol as required.)

#### Assay Procedure (96 well plate format):

1. Add 5 $\mu$ l of 5 x reaction buffer per assay to wells
2. Add 2.5 $\mu$ l of **CHKtide**.
3. Add **2.5 $\mu$ l (1.8–13.6ng) TSSK2, active**.
4. Add 5 $\mu$ l of dH<sub>2</sub>O.
5. Add 10 $\mu$ l of diluted [ $\gamma$ -<sup>33</sup>P]ATP mixture.
6. Incubate for 10 minutes at 30°C.
7. Stop the reaction by adding 5 $\mu$ l of 3% phosphoric acid.
8. Transfer a 10 $\mu$ l aliquot onto the appropriate area of a **P30 Filtermat**.
9. Wash the filtermat three times for 5 minutes with 75mM phosphoric acid.
10. Wash the filtermat once for 2 minutes with methanol.
11. Transfer the filtermat to a sealable plastic bag and add 4ml of scintillation cocktail.
12. Read in a scintillation counter. Compare cpm of enzyme samples with cpm of control samples that contain all assay components plus 1 $\mu$ l of 30% phosphoric acid.

## Certificate of Analysis

### TSSK2 Sequence Information

<b><u>Protein</u></b>	TSSK2
<b><u>Tags</u></b>	N-terminal 6His
<b><u>Native sequence</u></b>	M31 of the recombinant protein is equivalent to M1 of human TSSK2
<b><u>Accession number</u></b>	GenBank NM_053006

#### **Recombinant TSSK2 amino acid sequence:**

```

1 MSYYHHHHHH DYDIPTTENL YFQGAMDPEF MDDATVLRKK GYIVGINLGK GSYAKVKSAY
61 SERLKFNVAV KIIDRKKTP TDFVERFLPRE MDILATVNHG SIIKTYEIFE TSDGRIYIIM
121 ELGVQGDLE FIKCQALHE DVARKMFRQL SSAVKYCHDL DIVHRDLKCE NLLLDKDFNI
181 KLSDFGFSKR CLRDSNGRII LSKTFCGSAA YAAPEVLQSI PYQPKVYDIW SLGVILYIMV
241 CGSMPYDDSD IRKMLRIQKE HRVDFPRSKN LTCECKDLIY RMLQPDVSQR LHIDEILSHS
301 WLQPPKPKAT SSASFKREGE GKYRAECKLD TKTDLRPDHR PDHKLGAKTQ HRLLVVPENE
361 NRMEDRLAET SRAKDHHISG AEVGKAST

```

#### **Recombinant TSSK2 nucleotide sequence:**

```

1 atgtcgtact accatcacca tcaccatcac gattacgata tcccaacgac cgaaaacctg
61 tattttcagg ggcacatgga tccggaattc atggacgatg ccacagtcct aaggaagaag
121 ggttacatcg taggcatcaa tcttggaag ggttcctacg caaaagtcaa atctgcctac
181 tctgagcgcc tcaagttcaa tgtggctgtc aagatcatcg accgcaagaa aacacctact
241 gactttgtgg agagattcct tcctcgggag atggacatcc tggcaactgt caaccacggc
301 tccatcatca agacttacga gatctttgag acctctgacg gacggatcta catcatcatg
361 gagcttggcg tccagggcga cctcctcgag ttcacatcaagt gccagggagc cctgcatgag
421 gacgtggcac gcaagatggt ccgacagctc tcctccgccg tcaagtactg ccacgacctg
481 gacatcgctc accgggacct caagtgcgag aaccttctcc tcgacaagga cttcaacatc
541 aagctgtctg actttggctt ctccaagcgc tgcttgcggg acagcaatgg ggcgatcatc
601 ctgagcaaga ccttctgcgg gtcggcagca tatgcagccc ccgaggtgct gcagagcatc
661 ccctaccagc ccaaggtgta tgacatctgg agcctggggc tgatcctgta catcatggtc
721 tgcggtccca tgccctatga cgactccgac atcaggaaga tgctgcgtat ccagaaggag
781 caccgtgtgg acttcccgcg ctccaagaac ctgacctgag agtgcaagga cctcatctac
841 cgcatgctgc agcccagcgt cagccagcgg ctccacatcg atgagatcct cagccactcg
901 tggctgcagc cccccaagcc caaagccagc tcttctgcct cttcaagag ggagggggag
961 ggcaagtacc gcgctgagtg caaactggac accaagacag acttgaggcc cgaccaccgg
1021 cccgaccaca agcttgagc caaaaccag caccggctgc tgggtggtgcc cgagaacgag
1081 aacaggatgg aggacaggct ggccgagacc tccagggcca aagaccatca catctccgga
1141 gctgaggtgg ggaagcaag cacctag

```

Reviewed and approved by site quality representative.

Unless otherwise stated in our catalogue or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

© 2014 Eurofins Pharma Discovery Services UK Limited is an independent member of Eurofins Discovery Services.